Ac Immune Stock Today
| ACIU Stock | USD 3.38 0.09 2.74% |
Performance3 of 100
| Odds Of DistressLess than 8
|
AC Immune is selling for under 3.38 as of the 22nd of November 2024; that is 2.74 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.21. AC Immune has only a 8 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for AC Immune are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of September 2024 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of September 2016 | Category Healthcare | Classification Health Care |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. The company has 98.94 M outstanding shares of which 984.46 K shares are presently shorted by private and institutional investors with about 12.24 trading days to cover. More on AC Immune
Moving against ACIU Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
ACIU Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO CoFounder | Andrea Pfeifer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAC Immune can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand AC Immune's financial leverage. It provides some insight into what part of AC Immune's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AC Immune (ACIU) is traded on NASDAQ Exchange in USA. It is located in Building B, Lausanne, Switzerland, 1015 and employs 133 people. AC Immune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 325.52 M. AC Immune conducts business under Biotechnology sector and is part of Health Care industry. The entity has 98.94 M outstanding shares of which 984.46 K shares are presently shorted by private and institutional investors with about 12.24 trading days to cover.
AC Immune currently holds about 154.15 M in cash with (60.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
Check AC Immune Probability Of Bankruptcy
Ownership AllocationAC Immune secures a total of 98.94 Million outstanding shares. AC Immune shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check ACIU Ownership Details
ACIU Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Millennium Management Llc | 2024-06-30 | 106.4 K | |
| Two Sigma Investments Llc | 2024-06-30 | 99.3 K | |
| Eversept Partners, Llc | 2024-09-30 | 99.3 K | |
| Alps Advisors Inc | 2024-06-30 | 77.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 57.1 K | |
| Geode Capital Management, Llc | 2024-06-30 | 54.8 K | |
| Cubist Systematic Strategies, Llc | 2024-06-30 | 54.6 K | |
| Jump Financial Llc | 2024-06-30 | 41.3 K | |
| Citadel Advisors Llc | 2024-06-30 | 34.8 K | |
| Bvf Inc | 2024-09-30 | 19.5 M | |
| Blackrock Inc | 2024-06-30 | 2.6 M |
AC Immune Historical Income Statement
ACIU Stock Against Markets
AC Immune Corporate Management
| Julian Snow | VP Development | Profile | |
| Nuno MD | Chief Officer | Profile | |
| Christopher Roberts | Interim Fin | Profile | |
| Sonia Poli | Head Science | Profile | |
| Piergiorgio Donati | Chief Officer | Profile | |
| Pr MD | Chief Officer | Profile | |
| Joshua Drumm | Head Relations | Profile |
Already Invested in AC Immune?
The danger of trading AC Immune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AC Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AC Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AC Immune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.